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Purpose: The MET receptor is involved in the pathogenesis and
progression of non-small cell lung cancer (NSCLC). Clinical trials
with MET inhibitors in NSCLC are planned with patient selection
based on immunohistochemistry (IHC) and/or gene copy number
assessment. Therefore, a detailed understanding of relationship be-
tween these markers and prognosis is essential.
Methods: This study included tumors from 189 patients with
NSCLC who underwent pulmonary resection (median follow-up,
5.3 years). MET expression was evaluated by IHC on tissue mi-
croarrays and scored according to hybrid (H) score (range: 0–400)
and by scoring system used in the MetMAb trial (50% of cells
with moderate or strong staining). MET gene copy number was
assessed by silver in situ hybridization (n  140 patients).
Results: Median MET IHC H score was 60 (range: 0–400; n 174).
There were no associations between clinical and pathological charac-
teristics, disease-free survival, and overall survival according to median
value (p  0.36 and p  0.38, respectively), or other cut-points.
According to MetMAb scoring criteria, IHC positivity rate was 25%,
again with no associations to clinicopathological features or survival. In
140 tumors evaluable for MET copy number, 3 (2.1%) showed gene
amplification and 14 (10%) had tumors with average of 5 or more
copies per nucleus. There were no associations of MET copy number
with clinical characteristics, disease-free survival, or overall survival with
any analyzed cut-points. Correlation between MET copy number and
protein expression was significant (Pearson’s r  0.42, p  0.0001).
Conclusions: There is a significant correlation between MET pro-
tein expression and MET gene copy number in operable NSCLC, but
neither is associated with prognosis.
Key Words: MET gene copy number, MET protein expression,
Prognosis, Non-small cell lung cancer.
(J Thorac Oncol. 2012;7: 340–347)
Non-small cell lung cancer (NSCLC) represents a spec-trum of tumors with distinct biological characteristics
driven by different molecular aberrations. Several oncogenes
involved in the pathogenesis of NSCLC encode growth factor
receptors and related signaling molecules. Experimental and
translational studies support involvement of the MET onco-
gene in the development and progression of NSCLC.1,2 MET
is a receptor for hepatocyte growth factor (HGF)/scatter
factor with tyrosine kinase activity, encoded by a single gene
located at 7q31. During embryonic life, MET receptors are
expressed on epithelial cells and mediate epithelial to mes-
enchymal transition as well as on muscle precursor cells and
are essential for limb bud development.3
The MET gene is composed of 21 exons encoding the
following protein domains: HGF-binding semaphorin do-
main, transmembrane domain and juxtamembrane region
with regulatory role for tyrosine kinase activity, tyrosine
kinase domain, and carboxy-terminal tail.1 MET abnormali-
ties in NSCLC include protein overexpression,4 increased
gene copy number including amplifications,5 mutations in the
semaphorin domain,4 or mutations disrupting splice consen-
sus sequence leading to aberrant splice variants with exon 14
(juxtamembrane regulatory region) deletions.6
In patients with tumors harboring activating epidermal
growth factor receptor (EGFR) mutations and treated with
EGFR tyrosine kinase inhibitors (TKIs), MET amplification
represents one of the mechanisms of acquired resistance to
anti-EGFR therapy.7 An in vitro model of acquired resistance
caused by MET amplification demonstrated restoration of cell
line sensitivity to EGFR TKI when the cells are exposed to a
MET inhibitor.7,8 Combination of EGFR and MET inhibitors
is an emerging therapeutic strategy for overcoming resistance
to EGFR TKIs in NSCLC.7
A combination of EGFR and MET inhibitors was
recently studied in two randomized phase II clinical trials in
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unselected patients with NSCLC. These studies showed the
usefulness of MET gene copy number and/or immunohisto-
chemistry (IHC) evaluation in patient selection to this ther-
apy.9,10 The ARQ 209 trial (ArQule, Woburn, MA) compared
erlotinib alone with erlotinib combined with ARQ 197, a
non-ATP competitive inhibitor of MET, in patients with
advanced NSCLC who had failed first-line chemotherapy.9
No difference in progression-free survival (PFS) or overall
survival (OS) was seen in unselected patients with NSCLC.
However, patients harboring tumors with more than 5 copies
of the MET gene assessed by fluorescence in situ hybridiza-
tion (FISH) had increased PFS with the combination of
erlotinib and ARQ 197 (hazard ratio [HR]  0.45). The
second study, OAM4558g (Genentech, South San Francisco,
CA), compared erlotinib plus placebo with erlotinib plus
MetMAb, a MET-specific monovalent monoclonal antibody,
in second- or third-line treatment of NSCLC.10 No apparent
difference in outcome was observed in unselected patients,
but in the patients with high (2/3) MET protein expres-
sion by IHC, a clinical benefit in PFS and OS (PFS HR 
0.56, p  0.05; OS HR  0.55, p  0.11) was seen. The
median PFS was improved from 6.4 to 12.4 weeks. Of note,
in the experimental arm, patients with tumors showing no or
low MET protein expression showed worse PFS (HR 2.01)
and OS (HR  3.02), indicating that proper patient selection
is absolutely essential in further clinical trials with this
combination. Therefore, establishing an optimal technique for
determining MET status is highly clinically important.
In clinical practice, the most widely used technology
for gene copy number determination, particularly for HER2
in breast cancer, has for many years been FISH. Silver in situ
hybridization (SISH) for gene copy assessment is a new
technology with some clinical advantages compared with
FISH. First, assessment can be made using conventional light
microscopy with preserved cell structure based on an auto-
mated platform. In addition, the slides are stable and can be
revisited several years after the staining.11 Thus, SISH might
be more easily applied in routine clinical practice.
In this study, we compared MET gene copy number by
SISH and MET protein expression by IHC using the SP44
antibody, the same as used in the MetMAb study,10 in a
consecutive series of patients with NSCLC who underwent
pulmonary resection. The results of this study are aimed to
provide baseline biomarker data for future clinical trials
based on MET inhibition in NSCLC.
PATIENTS AND METHODS
Patient Population
The study group included 189 consecutive patients with
NSCLC who underwent pulmonary resection at the Medical
University of Gdansk, Poland (Table 1).12 The median fol-
TABLE 1. MET Protein Expression and Gene Copy Number versus Patient Characteristics
Characteristics All
MET Protein Expression MET Gene Copy Number
<60 >60 p <3.12 >3.12 p
n (%) 189 91 83 70 70
Age
Median (range) 64 (37–85) 63 (44–81) 66 (37–85) 0.10 66 (37–78) 65 (44–85) 0.70
Gender, n (%)
Female 45 (24) 19 (21) 20 (24) 0.72 14 (20) 17 (24) 0.54
Male 144 (76) 72 (79) 63 (76) 56 (80) 53 (76)
Smoking status, n (%)
Ever 180 (95) 85 (93) 80 (96) 0.50 65 (93) 67 (96) 0.47
Never 9 (5) 6 (7) 3 (4) 5 (7) 3 (4)
Histology, (%)
AC 55 (29) 28 (31) 21 (25) 0.74 17 (24) 20 (29) 0.84
SCC 103 (54) 50 (55) 47 (57) 40 (57) 40 (57)
LCC 5 (3) 3 (3) 2 (2) 2 (3) 3 (4)
NOS/mixed 26 (14) 10 (11) 13 (16) 11 (16) 7 (10)
Pathological stage, n (%)
I 75 (40) 39 (43) 30 (36) 0.14 19 (27) 31 (44) 0.21
II 42 (22) 15 (17) 25 (30) 22 (31) 11 (16)
III 61 (32) 32 (35) 23 (28) 25 (36) 21 (30)
IV 8 (4) 3 (3) 4 (5) 4 (6) 4 (6)
Missing 3 (2) 2 (2) 1 (1) 0 (0) 3 (4)
Grade, n (%)
G1 20 (11) 10 (11) 9 (11) 0.97 7 (10) 9 (13) 0.86
G2 81 (43) 37 (41) 36 (43) 30 (43) 29 (41)
G3 63 (33) 31 (34) 27 (33) 23 (33) 22 (31)
Missing 25 (13) 13 (14) 11 (13) 10 (14) 10 (14)
AC, adenocarcinoma; SCC, squamous cell carcinoma; LCC, large cell carcinoma; NOS, not otherwise specified.
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low-up in the entire group was 5.3 years (range: 1.1–6.9
years). Clinical data were derived from patient records. Tu-
mor type and grade (well, moderately, or poorly differenti-
ated) were reassessed by a local pathologist before tissue
microarray (TMA) construction according to World Health
Organization 2004 criteria.13 Tissue banking and current
research were approved by the institutional review boards at
the University of Colorado Cancer Center and the Medical
University of Gdansk. All patients provided informed consent
for tissue banking, and their data were anonymized according
to regulatory requirements.
TMA, Protein Expression, and Gene Copy
Number Evaluation
TMAs were created using MaxArray-customized TMA
service (Invitrogen, South San Francisco, CA) as described
previously.12 In brief, three tissue cores of 1.5 mm diameter
were obtained from different areas of primary tumor of each
patient. IHC evaluation was performed using antitotal c-MET
(SP44) rabbit monoclonal primary antibody (catalog
7904430; Ventana Medical Systems, Tucson, AZ). The stain-
ing was carried out according to the manufacturer’s protocol
on the BenchMark XT platform from Ventana using the
ultraView detection kit. A primary antibody was incubated
for 16 minutes. The IHC scoring was done by one pathologist
(B.R.A.) using the H-score assessment combining staining
intensity (0–4) and the percentage of positive cells (0–
100%).14 Each individual intensity level was multiplied by
the percentage of cells, and all values were added to obtain
the final IHC score, ranging from 0 to 400. The final score
was based on a combined assessment of membranous and
cytoplasmic expression.14 For each patient, the maximal re-
sult from three cores was used, and a tumor sample was
considered IHC positive if the score was above median.
Given the results of OAM4558g MetMAb phase II trial in
advanced NSCLC, additional evaluation was performed ac-
cording to MetMAb IHC-defined scoring criteria (positivity
defined as having 50% of tumor cells positive for membra-
neous MET immunostaining with moderate or strong inten-
sity, i.e., 2).10
MET gene copy number was analyzed using bright-field
microscopy and the SISH technology. Probing was carried
out using both MET-specific and centromere 7 (CEP7)-spe-
cific probes according to the protocols from the manufacturer
(Ventana Medical Systems; Figures 1E–H). The assessment
of gene copy number was performed independently and
blinded from IHC by another pathologist (S.S.). The scoring
was carried out in 50 nonoverlapping nuclei per core in
regions identified by optical analysis of tissue sections as
having higher gene copy number. The following data were
recorded for each sample: mean MET gene and mean CEP7
copy number per cell and MET/CEP7 ratio. The reading was
done for each core in the TMA, and the core with the highest
average MET gene copy number per cell was selected for
each patient as described previously.15 Small MET gene
clusters were scored as 6, and big clusters were scored as 12
signals, similarly to HER2 breast cancer practice.11 The
correlation between the highest and the average values for
three cores of the same patient was very high (r  0.98);
FIGURE 1. Representative examples of MET immunohisto-
chemical staining (A–D) with the SP44 antibody. The MET
silver in situ hybridization reaction resulted in black signals,
precipitated silver particles, whereas the CEP7 alkaline phos-
phatase–driven reaction resulted in red signals (E–H). H
score of 10 (A), 100 (B), 240 (C), and 380 (D); 2.76 MET
genes and 3.04 CEP7 centromeric regions per nucleus (E);
3.2 MET and 1.88 CEP7 (F); 5.66 MET and 4.56 CEP7 (G);
and 10.58 MET and 1.96 CEP7 (H).
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hence, it is unlikely that the choice of average value would
lead to different results.
Statistical Analysis
2 and Fisher’s exact tests were used to compare
categorical variables. Continuous variables were compared
using Mann-Whitney U test or Kruskal-Wallis test. The
correlations between two continuous variables were analyzed
using Pearson’s method. Survival curves were plotted using
Kaplan–Meier method counting survival time from the date
of operation to the date of death of any cause or the date of
last follow-up. Disease-free survival (DFS) was defined as
the time between date of operation and date of local or distant
progression, death of any cause (defined as event), or date of
last follow-up. Univariate and multivariate survival analyses
were performed with log-rank test and Cox proportional
hazard regression. A significance level of  less than or equal
to 0.05 was used without adjustment for multiple testing. All
reported p values are two sided. The calculations were done
using SAS statistical package (version 9.2; SAS Institute Inc.,
Cary, NC) and GraphPad Prism (version 5.0d; GraphPad
Software, La Jolla, CA).
RESULTS
MET Protein Expression by IHC
The results of MET staining were available in 174
patients (92%). The pattern of immunostaining was both
cytoplasmic and membranous. The examples of samples with
various staining intensities are shown in Figures 1A–D.
Median MET IHC score was 60 (range: 0–400), and
the mean was 91 (standard deviation: 96). There were eight
patients with an exact score of 60, resulting in 91 patients in
the group with a score of less than or equal to 60 and 83
patients in the group with a score of more than 60, and 117
patients (68%) showed MET IHC score more than 10. With
regard to histology, the mean H score was 91 (113) for
adenocarcinoma, 86 (86) for squamous cell carcinoma, 91
(81) for large cell carcinoma, and 110 (100) for other
types. The complete distribution of IHC scores is shown in
Figure 2A. Using median IHC score for the population as the
cutoff point, there were no significant associations between
MET protein expression and clinical and pathological char-
acteristics (Table 1). In particular, there were no differences
according to gender (p  0.72), smoking status (p  0.50),
histology (p  0.74), or pathological stage (p  0.14).
When MET IHC was evaluated according to MetMAb
scoring system, 25% of samples (44 of 174) were positive.
The number of IHC positive and negative cases for adeno-
carcinoma was 14 and 35, for squamous cell carcinoma 22
and 75, for large cell carcinoma 1 and 4, and for all others 7
and 16, respectively. There was no significant association
with clinical or pathological characteristics, including patho-
logical stage (all p values  0.05, data not shown).
No statistical difference in DFS or OS was seen be-
tween patients with tumors showing high versus low MET
protein expression, as defined by the median (IHC score 60
versus 60; log-rank p  0.36 and p  0.38, respectively;
Figure 3A). Similarly, there was no difference in either DFS
or OS when the positivity H-score cutoff was defined at 200
(log-rank p  0.99 and p  1.00, respectively; Figure 3C).
When adjusted for stage, age, gender, histology, and smoking
status, MET IHC score that was analyzed as a continuous
variable showed no statistical association with DFS (HR 
1.00; p  0.61) or OS (HR  1.00; p  0.46). We observed
no association of MET protein expression with DFS or OS
when MetMAb study criteria were used (log-rank p  0.86
and p  0.98, respectively, data not shown).
MET Gene Copy Number by SISH
Valid results for MET gene copy number were obtained
for 140 patients (74%). In the samples from the remaining 49
patients, the lack of valid result was primarily due to insuf-
ficient number of tumor cells in depleted cores (21 patients,
43% of missing results), insufficient or weak signals for MET
or CEP7 probe (27 patients, 55%), or other reasons (black
pigment in cells or poor structure, 1 patient, 2%). The above
findings suggest that missing data were at random and do not
bias the analysis. The examples of specimens with varying
levels of copy number are shown in Figures 1E–H. The
median value of average MET gene copy number per cell was
3.12 with a range of 1.74 to 11.84. There were three patients
with MET gene clusters corresponding to gene amplification
FIGURE 2. Histograms showing distribution, frequency,
median, range, mean, and standard deviation of MET pro-
tein expression (A) and MET/CEP7 gene copy number (B).
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(2.1%), and 14 patients (10.0%) had tumors with an average
MET gene copy number more than 5 per nucleus (cutoff point
established in a study using FISH).4 With regard to histology,
the mean gene copy number was 3.6 (1.8) for adenocarci-
noma, 3.3 (1.3) for squamous cell carcinoma, 3.6 (1.5)
for large cell carcinoma, and 3.2 (1.6) for other types. The
distribution of the copy number for the entire evaluable
population is shown in Figure 2B. We found no association of
MET gene copy number and demographic or clinical features,
including sex (p  0.54), stage (p  0.21), tumor grade (p 
0.86), histology (p  0.84), or smoking status (p  0.47;
Table 1). Using cutoffs for MET gene copy number of less
than or equal to 3.12 versus more than 3.12 or less than or
equal to 5.0 versus more than 5.0, there were no differences
in DFS (log-rank p  0.12 and log-rank p  0.65, respec-
tively, figures not shown) or OS (log-rank p  0.33 and
log-rank p  0.47, respectively, Figures 3B, D). There were
no DFS or OS differences when MET/CEP7 ratio was ana-
lyzed according to the median value of 1.29 (log-rank p 
0.47 and log-rank p  0.39, figures not shown). In the
multivariate Cox regression model adjusted for demographic
and clinical features, HRs of MET gene copy number ex-
pressed as a continuous variable for DFS and OS were 0.88
(95% confidence interval [CI], 0.72–1.07; p 0.19) and 0.90
(95% CI, 0.73–1.10; p  0.29), respectively.
Association between MET Gene Copy Number
and MET Protein Expression
The specimens for analysis of both MET gene copy
number and protein expression status were available for 138
patients (73% of overall study population). There was a
significant association between MET gene copy number and
protein expression (both variables analyzed as continuous
data, Pearson’s r  0.42, 95% CI  0.28–0.55, p  0.0001;
Figure 4A). When tumors were categorized according to
MET IHC score of 0 to 100, 101 to 200, 201 to 300, and 301
to 400, the corresponding medians for average gene copy
number values were 2.99, 3.24, 4.66, and 4.15 (Kruskal-
Wallis p  0.015; Figure 3B). Figure 4 shows the number of
patients in each IHC category according to gene copy num-
ber. All patients who had true amplification (clusters) or a
gene copy number more than 5 had positive MET protein
expression.
DISCUSSION
This study represents the first combined analysis of
MET gene copy number by SISH and protein expression by
IHC in NSCLC. Both assessments are widely applicable to
clinical specimens because of processing on the automated
platform and analysis under bright-field microscopy with
preserved cell structure. We demonstrated a significant cor-
relation between MET gene copy number by SISH and
protein expression by IHC, but neither was associated with
any clinical or pathological variables. In particular, all pa-
tients with more than 5 copies per cell (10% of the patients)
had high MET protein expression. The predictive value of
IHC for anti-MET therapy warrants further investigations in
prospective trials.
FIGURE 3. Overall survival (OS) probability curves accord-
ing to MET immunohistochemistry score using either the
median (A) or 200 (C) as cutoff points. OS probability curves
according to MET gene copy number by silver in situ hybrid-
ization using either the median (B) or 5 (D) as cutoff points.
Log-rank p values and univariate hazard ratios with corre-
sponding 95% confidence intervals are provided.
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The prognostic value of MET protein expression by
IHC was assessed in a few studies in operable NSCLC.16–18
The study of Masuya et al.16 including 88 patients with
NSCLC showed worse survival in those with MET IHC
positive tumors, defined by the presence of tumor cells with
staining intensity ranging from 2 to 4 (40.9% positivity rate).
Ichimura et al.18 used primary tumors from 104 surgically
resected patients with NSCLC and Western blot analysis
followed by IHC to demonstrate a tendency for worse sur-
vival in patients with tumoral MET expression. In contrast to
these data, using clinically applicable anti-MET antibody and
well-defined scoring systems, no survival impact of high
MET protein expression was found in our study. Other
studies indicated the importance of MET ligand (HGF) au-
tocrine19 or paracrine stimulation.16 This interaction was not
analyzed in our study.
In the MetMAb clinical trial10 including patients with
advanced NSCLC, the prevalence of MET IHC positivity was
51%, when compared with 25% in our population of operable
patients, according to the same scoring system and using the
same antibody. This difference might reflect a higher rate of
strong MET protein expression in advanced NSCLC com-
pared with early disease or may result from differences in
clinicopathological characteristics between both series. We
found no prognostic association of high MET protein expres-
sion according to the MetMab study criteria.
MET gene copy number has been a subject of several
studies using different methodologies, including in situ hy-
bridization (ISH) techniques4,20 and quantitative polymerase
chain reaction.6,21–24 Our report is the first analysis of MET
gene copy number using SISH technology, which is directly
applicable to clinical studies, as SISH has been recently
approved by the Food and Drug Administration for HER2
diagnostics in breast cancer. Importantly, the results of gene
dosage evaluation by ISH techniques and quantitative poly-
merase chain reaction may lead to different results and are not
directly comparable due to methodological differences, as
previously demonstrated for EGFR.25 FISH requires special-
ized microscopic equipment and suffers from fading of fluo-
rochromes, which makes the long-term stability of specimens
problematic. In addition, the interobserver variability is rel-
atively high because of the possibility of misinterpretation of
signal versus noise and possible signal assessment in nonma-
lignant cell nuclei. This means that FISH requires a learning
curve, and only persons experienced in FISH interpretation
should read the slides.11 FISH is also time-consuming, non-
automated, and expensive.
Frequencies of high MET gene copy number (average
5 signals per nucleus) in the two studies using FISH were
11.1% and 12.8%.4,20 These numbers are very similar to
10.0% in our report. In the first of the earlier mentioned
studies, the median of mean gene copy number per cell in the
entire cohort was 3.27,4 compared with 3.12 in the present
series. The frequency of true gene amplification in these
studies was approximately 4%4,20 versus 2.1% in our mate-
rial. Although data on MET gene copy number by SISH and
FISH have never been directly compared in lung cancer
specimens, based on the earlier data, we speculate that both
ISH techniques yield comparable results, and the clinical
applicability favors SISH.
Two studies showed adverse prognostic impact of high
MET gene copy number in NSCLC.4,18 In fact, in one of these
studies, patients with tumors showing more than or equal to
FIGURE 4. Scattergram comparing MET immunohisto-
chemistry (IHC) score to MET gene copy number for each
patient and treating both as a continuous variable (A). Me-
dian values of MET gene copy number per cell according to
MET-categorized IHC scores (B). Number of patients within
each IHC score category relative to MET gene copy number
categorized in whole number increments (C).
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4 to 5 copies per cell had the best prognosis, those with more
than or equal to 5 to 6 copies per cell had the worst prognosis,
whereas those with 2 to 5 copies per cell constituted the
intermediate group.4 The remarkable biological distinction of
exact 4 copies per cell was not explained in that study.4 These
results were not confirmed by other authors22,24 and in our
series. The adjusted HR for MET gene copy number analyzed
as a continuous variable (HR  0.90; 95% CI, 0.74–1.10)
indicates that the true negative impact of high MET gene copy
number is unlikely. The reason for differences between our
results and those previously reported with respect to prog-
nostic significance of MET gene copy number is unclear. It is
unlikely that a higher proportion of patients with squamous
cell carcinoma in our series accounts for this discrepancy,
because in one of the earlier studies, the negative prognostic
impact of MET gene copy number was confined to squamous
cell carcinomas only.20 It is possible that sample size did not
provide enough statistical power to detect a modest HR. The
size of the evaluable cohort (n 140), divided at the median,
provides 80% statistical power to detect as a statistically
significance HR of less than 0.53 or more than 2.26. Taking
into account the results of this study, it is difficult to speculate
on the biological meaning of high MET gene copy number in
early NSCLC. In most high-MET cases, the copy gain was
relatively modest, which may not activate MET receptors to
the degree affecting prognosis of patients with operable
NSCLC.
MET gene amplification was recently associated with
significant and durable response in a patient with NSCLC
receiving MET inhibitor on a phase I clinical trial.26 On the
basis of this case report and in vitro data, one may speculate
that high-level MET amplification is a driving molecular
event in NSCLC with potential diagnostic and clinical impli-
cations. The role of low-level copy gain remains to be
confirmed in prospective comparative clinical trials.
In conclusion, our study provides a detailed descriptive
analysis of relation between MET gene copy number and
MET protein expression. Using different comparisons, we
demonstrated a good association between these two markers,
and both may be considered for predicting sensitivity in
clinical trials with MET inhibitors. Our study demonstrated
no prognostic impact of MET protein expression by IHC or
gene copy number by SISH in a cohort of surgically treated
patients with NSCLC with adequate follow-up, which make
the potential predictive association with specific agents more
easily interpretable. The IHC assay used in the MetMab study
has demonstrated the clinical use; however, further standard-
ization and validation in prospective studies are warranted.
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